Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zimmer Closes Deal To Buy Chinese Device Company

This article was originally published in PharmAsia News

Executive Summary

Zimmer Holdings says it has closed a deal to acquire Beijing Montagne Medical Device, a maker of prosthetic devices and powered surgical devices

You may also be interested in...



Zimmer Looks To Score Big In Chinese Orthopedic Market With Beijing Montagne Acquisition

U.S.-listed orthopedic device maker Zimmer Inc. says its latest overseas purchase of Beijing Montagne Medical Device Co. Ltd., gives it greater marketing access to the Chinese orthopedic implant market, growing at an estimated 15 percent annually, and a manufacturing base to compete with rivals already in the market

‘Entirely New Theory Of Legal Liability’: FTC v. Amazon Is ‘Dark Patterns’ Case To Watch

Amazon’s motion to dismiss is pending in Washington State’s Western District in litigation concerning Prime subscriptions and alleged “dark patterns” used to trick consumers into enrolling and hinder cancellations, according to the US Federal Trade Commission. The case could be instructive for any and all digital marketers at a time of legal uncertainty surrounding the topic.

Lilly’s ‘High Quality’ Donanemab Data Supports Unrestricted Medicare Coverage, Firm Says

As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel